WO2023246837A1 - Classe de composés ayant une structure cyclique pyrimido à six chaînons, compositions pharmaceutiques les comprenant et leur utilisation - Google Patents
Classe de composés ayant une structure cyclique pyrimido à six chaînons, compositions pharmaceutiques les comprenant et leur utilisation Download PDFInfo
- Publication number
- WO2023246837A1 WO2023246837A1 PCT/CN2023/101588 CN2023101588W WO2023246837A1 WO 2023246837 A1 WO2023246837 A1 WO 2023246837A1 CN 2023101588 W CN2023101588 W CN 2023101588W WO 2023246837 A1 WO2023246837 A1 WO 2023246837A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substituted
- unsubstituted
- group
- substituents
- alkyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 136
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 12
- 201000010099 disease Diseases 0.000 claims abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 8
- 108700022176 SOS1 Proteins 0.000 claims abstract description 5
- 102000057028 SOS1 Human genes 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims abstract description 4
- 101100404726 Arabidopsis thaliana NHX7 gene Proteins 0.000 claims abstract 4
- 101100197320 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) RPL35A gene Proteins 0.000 claims abstract 4
- 101150100839 Sos1 gene Proteins 0.000 claims abstract 4
- 125000001424 substituent group Chemical group 0.000 claims description 77
- -1 cyano, amino, carboxyl Chemical group 0.000 claims description 63
- 125000000217 alkyl group Chemical group 0.000 claims description 61
- 229910052736 halogen Inorganic materials 0.000 claims description 42
- 150000002367 halogens Chemical class 0.000 claims description 42
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 37
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 36
- 125000000623 heterocyclic group Chemical group 0.000 claims description 33
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 26
- 229910052739 hydrogen Inorganic materials 0.000 claims description 26
- 238000006467 substitution reaction Methods 0.000 claims description 26
- 125000003545 alkoxy group Chemical group 0.000 claims description 25
- 150000003839 salts Chemical class 0.000 claims description 22
- 125000003118 aryl group Chemical group 0.000 claims description 21
- 239000001257 hydrogen Substances 0.000 claims description 21
- 229920006395 saturated elastomer Polymers 0.000 claims description 19
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 18
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 16
- 150000004677 hydrates Chemical class 0.000 claims description 15
- 229940002612 prodrug Drugs 0.000 claims description 15
- 239000000651 prodrug Substances 0.000 claims description 15
- 239000012453 solvate Substances 0.000 claims description 15
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 14
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 11
- 239000004480 active ingredient Substances 0.000 claims description 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 10
- 230000035772 mutation Effects 0.000 claims description 9
- 125000003277 amino group Chemical group 0.000 claims description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- 125000004043 oxo group Chemical group O=* 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 201000002927 Cardiofaciocutaneous syndrome Diseases 0.000 claims description 5
- 206010029748 Noonan syndrome Diseases 0.000 claims description 5
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 208000006334 Gingival Fibromatosis Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 125000000304 alkynyl group Chemical group 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 230000014509 gene expression Effects 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 208000002699 Digestive System Neoplasms Diseases 0.000 claims description 3
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims description 3
- 208000009849 Female Genital Neoplasms Diseases 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 206010073059 Malignant neoplasm of unknown primary site Diseases 0.000 claims description 3
- 206010027406 Mesothelioma Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 208000008938 Rhabdoid tumor Diseases 0.000 claims description 3
- 206010073334 Rhabdoid tumour Diseases 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 3
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 3
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 3
- 206010057644 Testis cancer Diseases 0.000 claims description 3
- 201000007455 central nervous system cancer Diseases 0.000 claims description 3
- 208000025997 central nervous system neoplasm Diseases 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 210000003734 kidney Anatomy 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 201000000349 mediastinal cancer Diseases 0.000 claims description 3
- 208000018280 neoplasm of mediastinum Diseases 0.000 claims description 3
- 201000008968 osteosarcoma Diseases 0.000 claims description 3
- 201000005528 peripheral nervous system neoplasm Diseases 0.000 claims description 3
- 201000000849 skin cancer Diseases 0.000 claims description 3
- 201000003120 testicular cancer Diseases 0.000 claims description 3
- 241000605059 Bacteroidetes Species 0.000 claims description 2
- 150000001335 aliphatic alkanes Chemical group 0.000 claims description 2
- 230000002068 genetic effect Effects 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 6
- 230000002401 inhibitory effect Effects 0.000 abstract description 10
- 102200006538 rs121913530 Human genes 0.000 abstract description 8
- 230000003993 interaction Effects 0.000 abstract description 6
- 229940126271 SOS1 inhibitor Drugs 0.000 abstract description 4
- 238000002474 experimental method Methods 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 64
- 238000006243 chemical reaction Methods 0.000 description 38
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 33
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 29
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 28
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 25
- 102000016914 ras Proteins Human genes 0.000 description 24
- 230000002829 reductive effect Effects 0.000 description 23
- 239000007787 solid Substances 0.000 description 23
- 239000012074 organic phase Substances 0.000 description 22
- 230000015572 biosynthetic process Effects 0.000 description 20
- 238000003786 synthesis reaction Methods 0.000 description 19
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 18
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 14
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 14
- 150000002431 hydrogen Chemical class 0.000 description 14
- 239000000203 mixture Substances 0.000 description 14
- 229910052757 nitrogen Inorganic materials 0.000 description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 10
- 239000012141 concentrate Substances 0.000 description 10
- 235000008504 concentrate Nutrition 0.000 description 10
- 108010014186 ras Proteins Proteins 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 9
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- 229910052786 argon Inorganic materials 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 230000002441 reversible effect Effects 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 102100030708 GTPase KRas Human genes 0.000 description 6
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000000460 chlorine Substances 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000010898 silica gel chromatography Methods 0.000 description 5
- 102000018898 GTPase-Activating Proteins Human genes 0.000 description 4
- 108091006094 GTPase-accelerating proteins Proteins 0.000 description 4
- 102000016285 Guanine Nucleotide Exchange Factors Human genes 0.000 description 4
- 108010067218 Guanine Nucleotide Exchange Factors Proteins 0.000 description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 125000001072 heteroaryl group Chemical group 0.000 description 4
- 125000001183 hydrocarbyl group Chemical group 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 125000006413 ring segment Chemical group 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- KOFLVDBWRHFSAB-UHFFFAOYSA-N 1,2,4,5-tetrahydro-1-(phenylmethyl)-5,9b(1',2')-benzeno-9bh-benz(g)indol-3(3ah)-one Chemical compound C1C(C=2C3=CC=CC=2)C2=CC=CC=C2C23C1C(=O)CN2CC1=CC=CC=C1 KOFLVDBWRHFSAB-UHFFFAOYSA-N 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 3
- 108700022174 Drosophila Son of Sevenless Proteins 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- 239000007821 HATU Substances 0.000 description 3
- 101000868154 Homo sapiens Son of sevenless homolog 2 Proteins 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 101000767160 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Intracellular protein transport protein USO1 Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 102100032930 Son of sevenless homolog 2 Human genes 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 235000011054 acetic acid Nutrition 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Substances CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 230000003301 hydrolyzing effect Effects 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 2
- GBBSAMQTQCPOBF-UHFFFAOYSA-N 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane Chemical compound CB1OB(C)OB(C)O1 GBBSAMQTQCPOBF-UHFFFAOYSA-N 0.000 description 2
- ADPCJMUNRPBSCO-UHFFFAOYSA-N 353281-15-9 Chemical compound OC(=O)C1=CC=NC(Cl)=C1[N+]([O-])=O ADPCJMUNRPBSCO-UHFFFAOYSA-N 0.000 description 2
- WCZUTMZMEAPPIX-UHFFFAOYSA-N 5-amino-2-chloropyridine-4-carboxylic acid Chemical compound NC1=CN=C(Cl)C=C1C(O)=O WCZUTMZMEAPPIX-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- 102100039788 GTPase NRas Human genes 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 208000030839 Hereditary gingival fibromatosis Diseases 0.000 description 2
- 101000624643 Homo sapiens M-phase inducer phosphatase 3 Proteins 0.000 description 2
- 101000580039 Homo sapiens Ras-specific guanine nucleotide-releasing factor 1 Proteins 0.000 description 2
- 101100446506 Mus musculus Fgf3 gene Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108091007960 PI3Ks Proteins 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 102000000113 Ral guanine nucleotide dissociation stimulator Human genes 0.000 description 2
- 108050008437 Ral guanine nucleotide dissociation stimulator Proteins 0.000 description 2
- 102100027551 Ras-specific guanine nucleotide-releasing factor 1 Human genes 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 description 2
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 description 2
- XPOLVIIHTDKJRY-UHFFFAOYSA-N acetic acid;methanimidamide Chemical class NC=N.CC(O)=O XPOLVIIHTDKJRY-UHFFFAOYSA-N 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 238000006482 condensation reaction Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- UZUODNWWWUQRIR-UHFFFAOYSA-L disodium;3-aminonaphthalene-1,5-disulfonate Chemical compound [Na+].[Na+].C1=CC=C(S([O-])(=O)=O)C2=CC(N)=CC(S([O-])(=O)=O)=C21 UZUODNWWWUQRIR-UHFFFAOYSA-L 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 230000026792 palmitoylation Effects 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- PARWUHTVGZSQPD-UHFFFAOYSA-N phenylsilane Chemical compound [SiH3]C1=CC=CC=C1 PARWUHTVGZSQPD-UHFFFAOYSA-N 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- XKOOYFHELMABPJ-SNVBAGLBSA-N tert-butyl n-[(1r)-1-(3-bromo-2-methylphenyl)ethyl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@H](C)C1=CC=CC(Br)=C1C XKOOYFHELMABPJ-SNVBAGLBSA-N 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- 125000002053 thietanyl group Chemical group 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- ONDSBJMLAHVLMI-UHFFFAOYSA-N trimethylsilyldiazomethane Chemical compound C[Si](C)(C)[CH-][N+]#N ONDSBJMLAHVLMI-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- LOPKSXMQWBYUOI-BDAKNGLRSA-N (1s,2r)-1-amino-2,3-dihydro-1h-inden-2-ol Chemical compound C1=CC=C2[C@H](N)[C@H](O)CC2=C1 LOPKSXMQWBYUOI-BDAKNGLRSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- LBNWYNIGDUWAOQ-UHFFFAOYSA-N 1-(3-bromo-2-methylphenyl)ethanone Chemical compound CC(=O)C1=CC=CC(Br)=C1C LBNWYNIGDUWAOQ-UHFFFAOYSA-N 0.000 description 1
- MFYNCTJUIOMWME-UHFFFAOYSA-N 1-bromo-3-(difluoromethyl)-2-fluorobenzene Chemical compound FC(F)C1=CC=CC(Br)=C1F MFYNCTJUIOMWME-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- CESUXLKAADQNTB-ZETCQYMHSA-N 2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@@](N)=O CESUXLKAADQNTB-ZETCQYMHSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- 125000002774 3,4-dimethoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- RLIMKKTUPNKGJS-UHFFFAOYSA-N 3-bromo-n-methoxy-n,2-dimethylbenzamide Chemical compound CON(C)C(=O)C1=CC=CC(Br)=C1C RLIMKKTUPNKGJS-UHFFFAOYSA-N 0.000 description 1
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 1
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- OAIMUUKRQQPSBG-UHFFFAOYSA-N CC(=O)C1=CC=CC(C(F)F)=C1F Chemical compound CC(=O)C1=CC=CC(C(F)F)=C1F OAIMUUKRQQPSBG-UHFFFAOYSA-N 0.000 description 1
- KQOCWZYNIHZYSG-UHFFFAOYSA-N CC[Ti](CC)(CC)CC.O Chemical compound CC[Ti](CC)(CC)CC.O KQOCWZYNIHZYSG-UHFFFAOYSA-N 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 101100015729 Drosophila melanogaster drk gene Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- ZRVVOUJFRYGVIT-UHFFFAOYSA-N FC(C1=C(C(=CC=C1)C(=C)OCC)F)F Chemical compound FC(C1=C(C(=CC=C1)C(=C)OCC)F)F ZRVVOUJFRYGVIT-UHFFFAOYSA-N 0.000 description 1
- XIWZLSFPKZDWMZ-UHFFFAOYSA-N F[S](F)F.CCNCC Chemical compound F[S](F)F.CCNCC XIWZLSFPKZDWMZ-UHFFFAOYSA-N 0.000 description 1
- 102100029974 GTPase HRas Human genes 0.000 description 1
- 101710204378 GTPase NRas Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- 102100033067 Growth factor receptor-bound protein 2 Human genes 0.000 description 1
- 108091009389 Growth factor receptor-bound protein 2 Proteins 0.000 description 1
- 241000713858 Harvey murine sarcoma virus Species 0.000 description 1
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 description 1
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 241000208167 Oxalis Species 0.000 description 1
- 235000008098 Oxalis acetosella Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 108010059447 Son of Sevenless Proteins Proteins 0.000 description 1
- 102000005588 Son of Sevenless Proteins Human genes 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000006619 Stille reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000008856 allosteric binding Effects 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- HGXJOXHYPGNVNK-UHFFFAOYSA-N butane;ethenoxyethane;tin Chemical compound CCCC[Sn](CCCC)(CCCC)C(=C)OCC HGXJOXHYPGNVNK-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- WLVKDFJTYKELLQ-UHFFFAOYSA-N cyclopropylboronic acid Chemical compound OB(O)C1CC1 WLVKDFJTYKELLQ-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- YDVNLQGCLLPHAH-UHFFFAOYSA-N dichloromethane;hydrate Chemical compound O.ClCCl YDVNLQGCLLPHAH-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 201000009409 embryonal rhabdomyosarcoma Diseases 0.000 description 1
- 231100001129 embryonic lethality Toxicity 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- XWBDWHCCBGMXKG-UHFFFAOYSA-N ethanamine;hydron;chloride Chemical compound Cl.CCN XWBDWHCCBGMXKG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 150000003947 ethylamines Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 101150098203 grb2 gene Proteins 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 102000009543 guanyl-nucleotide exchange factor activity proteins Human genes 0.000 description 1
- 108040001860 guanyl-nucleotide exchange factor activity proteins Proteins 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000005945 imidazopyridyl group Chemical group 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 150000004658 ketimines Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VFZXMEQGIIWBFJ-UHFFFAOYSA-M magnesium;cyclopropane;bromide Chemical compound [Mg+2].[Br-].C1C[CH-]1 VFZXMEQGIIWBFJ-UHFFFAOYSA-M 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 150000002696 manganese Chemical class 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- WCYAALZQFZMMOM-UHFFFAOYSA-N methanol;sulfuric acid Chemical compound OC.OS(O)(=O)=O WCYAALZQFZMMOM-UHFFFAOYSA-N 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 150000003956 methylamines Chemical class 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- HWWVAHCWJLGKLW-UHFFFAOYSA-N n,n-dimethylhydroxylamine;hydron;chloride Chemical class Cl.CN(C)O HWWVAHCWJLGKLW-UHFFFAOYSA-N 0.000 description 1
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000001175 peptic effect Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical class [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 230000013823 prenylation Effects 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 102000030938 small GTPase Human genes 0.000 description 1
- 108060007624 small GTPase Proteins 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229950000244 sulfanilic acid Drugs 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- JMXKSZRRTHPKDL-UHFFFAOYSA-N titanium ethoxide Chemical compound [Ti+4].CC[O-].CC[O-].CC[O-].CC[O-] JMXKSZRRTHPKDL-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- UAEJRRZPRZCUBE-UHFFFAOYSA-N trimethoxyalumane Chemical compound [Al+3].[O-]C.[O-]C.[O-]C UAEJRRZPRZCUBE-UHFFFAOYSA-N 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Definitions
- the invention belongs to the field of medicinal chemistry. Specifically, the present invention relates to a class of compounds having a pyrimido six-membered ring structure, their stereoisomers, racemates, geometric isomers, tautomers, prodrugs, hydrates, solvates or their Pharmaceutically acceptable salts, and pharmaceutical compositions containing them, which have SOS1 inhibitor activity.
- RAS proteins include KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog), HRAS (neuroblastoma RAS viral oncogene homolog) and NRAS (Harvey murine sarcoma virus oncogene), of which KRAS has two alternatively spliced isomers KRAS4A and KRAS4B.
- RAS protein is mainly distributed on the inside of the cell membrane, and membrane localization is a key step in activating RAS.
- RAS protein requires prenylation and palmitoylation of its C terminus, but due to the lack of palmitoylation site, the membrane localization of KRAS4B relies on the electrostatic interaction between the polybasic region composed of lysine and the plasma membrane.
- RAS protein belongs to the small GTPase family and exists in cells in a GTP-binding or GDP-binding manner. The activation of RAS protein requires its transition from a GDP-bound state to a GTP-bound state.
- GEFs guanine nucleotide exchange factors
- SOS1 Syn of Sevenless 1
- RAS activation will promote the activation of downstream effector molecules RAF, PI3K (Phosphoinositide 3-kinase) and RalGDS (Ral guanine nucleotide dissociation stimulator) to affect cell proliferation, growth, metabolism, migration, angiogenesis and other biological processes (Rodriguez-Viciana and McCormick, 2005; Young et al., 2009).
- RAS proteins have intrinsic hydrolytic activity that converts GTP into GDP.
- GTPase activating proteins can increase its hydrolysis rate to inactivate RAS.
- GAPs and GEFs strictly regulate the inactivation and activation of RAS protein, but when the RAS protein is mutated, the regulatory mechanism is dysregulated.
- RAS mutations in tumor cells mainly occur at positions G12, G13 and Q61. Mutations at these sites weaken endogenous and GAPs-mediated hydrolysis activities. Mutations at G13 and Q61 also increase the GTP exchange rate mediated by GEFs (Simanshu et al., 2017; Smith et al., 2013).
- the SOS1 protein has two important motifs, the RAS exchanger motif (REM) and the CDC25 homology domain, which are the allosteric binding site and the catalytic binding site respectively.
- REM RAS exchanger motif
- CDC25 binds RAS-GDP to promote the exchange of GDP and GTP
- REM binds RAS-GTP to further increase the catalytic activity of SOS1 (Freedman et al., 2006; Pierre et al., 2011).
- SOS1 plays a key role in KRAS mutant tumors. Knocking down SOS1 will reduce the proliferation and viability of KRAS mutant tumor cells, but has no effect on KRAS wild-type cells (Jeng et al., 2012).
- SOS1 plays an important role in activating the RAS signaling pathway. After activation of tyrosine kinase receptor RTKs, SHP2 is activated, binding to the adapter protein Grb2, promoting the formation of a complex between Grb2 and SOS1 and activating SOS1, thereby activating the RAS protein (Baltanas et al., 2020).
- SOS1 mutations exist in tumor cells, such as embryonal rhabdomyosarcoma, lung adenocarcinoma, etc. (Denayer et al., 2010), while SOS1 is highly expressed in bladder cancer and prostate cancer (Timofeeva et al., 2009; Watanabe et al. ,2000). In addition, SOS1 is also present in Noonan syndrome (NS), cardio-facio-cutaneous syndrome (CFC), hereditary gingival fibromatosis and related syndromes. mutation (Pierre et al., 2011).
- SOS2 the homolog of SOS1 also acts as a GEF to activate RAS proteins, and there is functional redundancy between the two.
- Knocking out SOS1 in mice results in embryonic lethality (Qian et al., 2000), while conditional knocking out of SOS1 in adult mice is viable (Baltanas et al., 2013).
- knocking out SOS2 in mice has no obvious phenotype (Esteban et al., 2000). If both SOS1 and SOS2 are knocked out in adult mice, the mice die quickly (Baltanas et al., 2013). Selective inhibition of individual SOS isoforms, such as SOS1, may be more effective in treating SOS1-RAS-activated diseases.
- Inhibiting the SOS1 catalytic site from binding to RAS can prevent SOS1-mediated RAS-GTP production and inhibit the RAS signaling pathway.
- RAS-dependent tumors such compounds can theoretically disrupt the combination of RAS and SOS, inhibit the phosphorylation of cellular ERK, and have anti-tumor effects.
- Compounds that inhibit the interaction between SOS1 and RAS can inhibit RAS activity and can be used to treat head and neck cancer, lung cancer, mediastinal tumors, gastrointestinal tumors, prostate cancer, testicular cancer, gynecological tumors, breast cancer, kidney and bladder cancer, and endocrine system tumors.
- soft tissue sarcoma soft tissue sarcoma, osteosarcoma, rhabdoid tumor, mesothelioma, skin cancer, peripheral nervous system tumors, central nervous system tumors, lymphoma, leukemia, unknown primary cancer, Noonan syndrome, cardiofaciocutaneous syndrome, Hereditary gingival fibromatosis and its associated syndromes.
- the invention provides a compound of formula (I), its enantiomers, diastereomers, racemates, prodrugs, hydrates, solvates or pharmaceutically acceptable salts thereof:
- ring A represents a C 6-10 aryl group, a 5-10 membered heteroaryl group or a 4-10 membered saturated or unsaturated heterocyclyl group; in particular, ring A is a phenyl group;
- n is an integer from 0 to 5;
- R 1 is selected from hydrogen, halogen, hydroxyl, unsubstituted or substituted C 1-6 alkyl, unsubstituted or substituted C 3-6 cycloalkyl, unsubstituted or substituted 4-10 membered saturated or unsaturated heterocycle group, unsubstituted or substituted C 1-6 alkoxy, -CN, -COOH, -CONH 2 , -CONH-C 1-6 alkyl, amino, -NH-C 1-6 alkyl; in particular, R 1 is selected from hydrogen, halogen, hydroxyl, unsubstituted or substituted C 1-4 alkyl, unsubstituted or substituted C 3-6 cycloalkyl, unsubstituted or substituted C 1-4 alkoxy, -CN , -COOH, amino; preferably, R 1 is selected from hydrogen, halogen, hydroxyl, -CN, methyl, ethyl, methoxy, ethoxy, amino,
- R 2 is hydrogen, unsubstituted or substituted C 1-6 alkyl, or unsubstituted or substituted C 3-6 cycloalkyl; in particular, R 2 is methyl or ethyl;
- R 4 is hydrogen, unsubstituted or substituted C 1-10 alkyl, unsubstituted or substituted C 6-10 aryl, unsubstituted or substituted 5-10 membered heteroaryl, unsubstituted or substituted C 3- 6- cycloalkyl, unsubstituted or substituted 4-10-membered saturated or unsaturated heterocyclyl, unsubstituted or substituted 5-10-membered heteroaryl and 4-10-membered heterocyclyl, halogen, -CN, -COOH , -OR 5 , -NH-R 5 , -CONH-R 5 , -NHCO-R 5 , -SO 2 -R 5 , or -SO 2 NH-R 5 ; preferably, R 4 is selected from unsubstituted or substituted C 1-10 alkyl, unsubstituted or substituted C 6-10 aryl, unsubstituted or substituted 5-6 membered heteroaryl
- R 5 is selected from hydrogen, unsubstituted or substituted C 1-10 alkyl, unsubstituted or substituted C 6-10 aryl, unsubstituted or substituted 5-10 membered heteroaryl, unsubstituted or substituted C 3 -6 cycloalkyl, unsubstituted or substituted 4-10 membered saturated or unsaturated heterocyclyl;
- substitution in R 1 , R 2 , R 4 and R 5 means substitution with one or more substituents from the following group A.
- the substituents in group A include: unsubstituted or one of the substituents in group B.
- One or more substituted C 1-6 alkyl, C 1-6 alkoxy, C 3-6 cycloalkyl, hydroxyl, halogen, cyano, amino, carboxyl, oxo group ( O), -NH-C 1-6 alkyl, -NH-C 3-6 cycloalkyl, unsubstituted or C 6-10 aryl substituted with one or more substituents of Group B, unsubstituted or substituted by Group B 5-10 membered heteroaryl substituted by one or more substituents, C 3-6 cycloalkyl unsubstituted or substituted by one or more substituents of Group B, unsubstituted or substituted by Group B One or more substituted 4-10-membered saturated or unsaturated hetero
- R2 is methyl or ethyl.
- Ring A is phenyl
- n is 1, 2 or 3; preferably, n is 1 or 2;
- Each R 3 is independently selected from: substituted or unsubstituted C 1-4 alkyl, substituted or unsubstituted C 2-4 alkynyl, substituted Or unsubstituted 4-6 membered saturated or unsaturated heterocyclic group, halogen, cyano group and amino group; the substitution refers to being substituted by one or more substituents selected from halogen, hydroxyl, cyano group and amino group ;Other substituents are as defined above.
- each R 3 is independently selected from: halogen, cyano, C 1-2 alkyl, halo C 1-2 alkyl; preferably, each R 3 is independently methyl, F , CN, CHF 2 or CF 3 ; more preferably, each R 3 is independently F or CHF 2 .
- R 1 is hydrogen, halogen, hydroxyl, unsubstituted or substituted C 1-4 alkyl, unsubstituted or substituted C 3-6 cycloalkyl, unsubstituted or substituted C 1-4 alkyl Oxygen, -CN, -COOH, or amino; the substitution means substitution with one or more selected from hydroxyl, halogen, cyano, and amino; preferably, R 1 is hydrogen, halogen, hydroxyl, -CN, methyl, ethyl, methoxy, ethoxy, amino, or cyclopropyl; more preferably, R 1 is hydrogen, halogen, -CN, methyl, methoxy, or cyclopropyl; Other substituents are as defined above.
- R 4 is selected from unsubstituted or substituted C 1-10 alkyl, unsubstituted or substituted C 6-10 aryl, unsubstituted or substituted 5-6 membered heteroaryl, unsubstituted or substituted C 3-6 cycloalkyl, unsubstituted or substituted 4-10 membered heterocyclyl;
- the 5-6 membered heteroaryl group is selected from: Preferably, the 5-6 membered heteroaryl group is selected from:
- the 4-10 membered heterocyclic group is selected from: Preferably, the 4-10 membered heterocyclic group is selected from
- R 4 means that it is substituted by one or more of the following substituents of Group A.
- the substituents of Group A include: C 1 which is unsubstituted or substituted by one or more of the substituents of Group B. -6 alkyl, C 1-6 alkoxy, C 3-6 cycloalkyl, hydroxyl, halogen, cyano, amino, carboxyl, -C(O)-R 6 , -C(O)-NH-R 6 ; R 6 is selected from hydrogen, unsubstituted or C 1-10 alkyl substituted by one or more of the substituents of Group B, unsubstituted or substituted by one or more of the substituents of Group B C 3-6 cycloalkyl;
- Group B substituents include: C 1-6 alkyl, C 1-6 alkoxy, hydroxyl, halogen, cyano, amino, carboxyl.
- R 4 is selected from C 1-10 alkyl which is unsubstituted or substituted by m substituents R 7 and the following structure:
- n 1, 2 or 3;
- R 7 and R 8 are each independently selected from H, C 1-6 alkyl, C 1-6 alkoxy, C 3-6 cycloalkyl, which is unsubstituted or substituted by one or more of the substituents in Group B. group, hydroxyl, halogen, cyano, amino, carboxyl, -C(O)-R 9 ;
- R 9 is selected from hydrogen, unsubstituted or C 1-10 alkane substituted by one or more of the substituents in Group B group, unsubstituted or C 3-6 cycloalkyl substituted by one or more of the substituents in Group B;
- Group B substituents include: C 1-6 alkyl, C 1-6 alkoxy, hydroxyl , halogen, cyano, amino, carboxyl;
- n 1 or 2;
- R 7 is selected from H, C 1-6 alkyl, C 1-6 alkoxy, C 3-6 cycloalkyl, hydroxyl , halogen, which is unsubstituted or substituted by one or more of the substituents of Group B.
- Group B substituents include: hydroxyl, halogen, cyano group, amino group;
- R 8 is selected from H, C 1-6 alkyl, C 1-6 alkoxy, -C(O)-R 9 ;
- R 9 is selected from C 1-6 alkyl, C 3-6 cycloalkyl;
- n 1 or 2;
- R 7 is selected from H, C 1-6 alkyl, C 1-6 alkoxy, C 3-6 cycloalkyl, hydroxyl , halogen, which is unsubstituted or substituted by one or more of the substituents of Group B.
- Group B substituents include: hydroxyl, halogen, cyano group, amino group;
- R 8 is selected from H, methyl, ethyl, methoxy, ethoxy, -C(O)-R 9 ;
- R 9 is selected from methyl, ethyl, cyclopropyl;
- R 4 is selected from C 1-6 alkyl substituted by hydroxyl and/or C 3-6 cycloalkyl and the following structure:
- R 7 and R 7 ' are selected from H, hydroxyl, amino, methyl, ethyl, methoxy, hydroxymethyl, hydroxyethyl, and R 8 is selected from H, methyl, ethyl, methoxy, -C(O)-R 9 ; R 9 is selected from methyl, ethyl, and cyclopropyl;
- R 1 is methyl, methoxy or cyclopropanyl.
- R 3 is F, CHF 2 , CF 3 or CN.
- the compound of formula (I) is represented by the following formula III:
- R 4 is defined as above respectively.
- the compound of formula (I) is selected from the following compounds:
- Another aspect of the invention provides a pharmaceutical composition
- a pharmaceutical composition comprising:
- Another aspect of the present invention provides the compound of formula (I), its enantiomers, diastereomers, racemates, prodrugs, hydrates, solvates or pharmaceutically acceptable compounds thereof. Acceptable salts, or the use of said pharmaceutical composition in the preparation of SOS1 inhibitors.
- Another aspect of the present invention provides the compound of formula (I), its enantiomers, diastereomers, racemates, prodrugs, hydrates, solvates or pharmaceutically acceptable compounds thereof.
- the diseases related to SOS1 mutation, activity or expression include head and neck cancer, lung cancer, mediastinal tumors, gastrointestinal tumors, prostate cancer, testicular cancer, gynecological tumors, breast cancer, kidney and bladder cancer, endocrine system tumors, Soft tissue sarcoma, osteosarcoma, rhabdoid tumor, mesothelioma, skin cancer, peripheral nervous system tumors, central nervous system tumors, lymphoma, leukemia, unknown primary cancer, Noonan syndrome, cardiofaciocutaneous syndrome, genetic Gingival fibromatosis and its related syndromes.
- the compound of the present application exhibits significantly excellent KRAS-G12C/SOS1 interaction inhibitory activity. Therefore, it has the potential to be an SOS1 inhibitor and can be developed into a therapeutic drug for diseases related to this.
- the group valency has a wavy line when, for example, , the wavy line indicates the point of attachment of the group to the rest of the molecule.
- the halogen is F, Cl, Br or I.
- C 1-6 means having 1, 2, 3, 4, 5 or 6 carbon atoms
- C 1-8 means having 1, 2, 3, 4, 5, 6 , 7 or 8 carbon atoms, and so on.
- 3- to 8-membered heterocyclyl refers to a heterocyclic group with 3-8 ring atoms, and so on, “4- to 10-membered heterocyclyl” and so on.
- alkyl refers to a saturated linear or branched hydrocarbon moiety.
- C 1-10 alkyl refers to a linear or branched alkyl group having 1 to 10 carbon atoms, without limitation. Specifically include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl and hexyl, etc.; preferably methyl, ethyl, propyl, isopropyl base, butyl, isobutyl, sec-butyl and tert-butyl.
- the C 1-10 alkyl group is preferably a C 1-6 alkyl group, and more preferably a C 1-4 alkyl group.
- alkoxy means an -O-(C 1-6 alkyl) group.
- C 1-6 alkoxy refers to a straight or branched chain alkoxy group having 1 to 6 carbon atoms, including without limitation methoxy, ethoxy, propoxy, iso Propoxy and butoxy etc.
- alkenyl refers to a linear or branched chain hydrocarbon moiety containing at least one double bond.
- C 2-6 alkenyl refers to a hydrocarbon group having 2 to 6 carbon atoms and containing one double bond.
- Straight-chain or branched alkenyl groups include, but are not limited to, vinyl, propenyl, butenyl, isobutenyl, pentenyl, hexenyl, and the like.
- cycloalkyl refers to a saturated cyclic hydrocarbon moiety.
- C 3-8 cycloalkyl refers to a cyclic alkyl group with 3 to 8 carbon atoms in the ring, without limitation. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and cyclodecyl, etc.
- aryl refers to a carbocyclic hydrocarbon group consisting of one ring or more, such as two fused rings, at least one of which is an aromatic ring.
- aryl groups include, but are not limited to, phenyl, naphthyl, and the like.
- heterocyclyl refers to a cyclic group containing at least one carbon atom and at least one (such as 1-3) cyclic heteroatoms selected from N, O, and S, specifically as used in this application.
- R is hydrogen, C 1-4 alkyl or nitrogen protecting group (for example, benzyloxycarbonyl, p-methoxybenzylcarbonyl, tert-butoxycarbonyl, acetyl , benzoyl, benzyl, p-methoxy-
- Heterocyclyl includes monocyclic, bridged, spiro and other bicyclic structures, such as 3- to 8-membered heterocyclyl, 3- to 6-membered heterocyclyl, etc.; such as tetrahydrofuranyl, pyrrolidinyl, oxyheterocycle Butyl, oxanyl, azetidinyl, oxiranyl, aziridinyl, thietanyl, 1,2-dithietanyl, 1,3-di Thietanyl, azepanyl, oxetanyl, etc.
- the term "5- to -10-membered heteroaryl” refers to a monomer having 5 to 10 ring atoms, such as 5, 6 or 7 ring atoms (ie, 5- to 7-membered heteroaryl).
- a cyclic or bicyclic or fused polycyclic cyclic aromatic hydrocarbon group which contains at least one (such as 1-3) ring heteroatoms independently selected from N, O and S (such as N) in the ring, and the remaining ring atoms Is a carbon atom; such as imidazolyl, pyridyl, pyrrolyl, thiazolyl, furyl, oxazolyl, isoxazolyl, pyrazolyl, thienyl, pyrimidinyl, 1,2,4-triazolyl, etc. ; Preferred is a five-membered heteroaryl group, such as imidazolyl, isoxazolyl, and 1,2,4-triazolyl.
- Bicyclic heteroaryl groups include, for example, benzoxazolyl, imidazopyridyl, triazolopyridyl, benzofuryl, pyrazolopyrimidinyl, benzodioxolyl, indolyl , quinolyl, isoquinolyl, etc.
- the substitution is mono-substitution or poly-substitution
- the poly-substitution is disubstitution, tri-substitution, tetra-substitution or penta-substitution.
- the disubstituted means having two substituents, and so on. In the case of polysubstitution, the substituents may be the same as or different from each other.
- the pharmaceutically acceptable salt described in the present invention may be a salt formed by an anion and a positively charged group on the compound of formula (I).
- Suitable anions are chloride, bromide, iodide, sulfate, nitrate, phosphate, citrate, methanesulfonate, trifluoroacetate, acetate, malate, tosylate, tartrate, fumarate Acid, glutamate, glucuronate, lactate, glutarate or maleate.
- salts can be formed from cations with negatively charged groups on compounds of formula I. Suitable cations include sodium, potassium, magnesium, calcium and ammonium ions, such as tetramethylammonium.
- “pharmaceutically acceptable salts” refer to salts formed by the compound of formula (I) with an acid selected from the following group: hydrofluoric acid, hydrochloric acid, hydrobromic acid, phosphoric acid, acetic acid, oxalic acid, Sulfuric acid, nitric acid, methanesulfonic acid, sulfamic acid, salicylic acid, trifluoromethanesulfonic acid, naphthalenesulfonic acid, maleic acid, citric acid, acetic acid, lactic acid, tartaric acid, succinic acid, wood sorrel Acid, pyruvic acid, malic acid, glutamic acid, p-toluenesulfonic acid, naphthalenesulfonic acid, ethanesulfonic acid, naphthalenedisulfonic acid, malonic acid, fumaric acid, propionic acid, oxalic acid, trifluoroacetic acid, stealic acid,
- “Therapeutically effective amount” refers to the amount of active ingredient sufficient to significantly improve the condition without causing serious side effects.
- pharmaceutical compositions typically contain 1-2000 mg active ingredient/dose, more preferably, 10-200 mg active ingredient/dose.
- the "dose” is a tablet.
- “Pharmaceutically acceptable carrier” refers to one or more compatible solid or liquid filler or gel substances that are suitable for human use and must be of sufficient purity and low enough toxicity. "Compatibility” here refers to the ability of each component of the composition to be blended with the active ingredients of the present invention and with each other without significantly reducing the efficacy of the active ingredients.
- Some examples of pharmaceutically acceptable carriers include cellulose and its derivatives (such as sodium carboxymethylcellulose, sodium ethylcellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (such as stearin acid, magnesium stearate), calcium sulfate, vegetable oils (such as soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (such as propylene glycol, glycerin, mannitol, sorbitol, etc.), emulsifiers (such as ), wetting agents (such as sodium lauryl sulfate), colorants, flavorings, stabilizers, antioxidants, preservatives, pyrogen-free water, etc.
- cellulose and its derivatives such as sodium carboxymethylcellulose, sodium ethylcellulose, cellulose acetate, etc.
- gelatin such as sodium carboxymethylcellulose, sodium ethylcellulose, cellulose acetate, etc.
- talc such as sodium carb
- the administration mode of the active ingredients or pharmaceutical compositions of the present invention is not particularly limited.
- Representative administration modes include (but are not limited to): oral, intratumoral, rectal, parenteral (intravenous, intramuscular or subcutaneous), etc.
- Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules.
- Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or tinctures.
- liquid dosage forms may contain inert diluents conventionally used in the art, such as water or other solvents, solubilizers and emulsifiers, for example, ethanol, isopropyl alcohol, ethyl carbonate, ethyl acetate, propylene glycol, 1 , 3-butanediol, dimethylformamide and oils, especially cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil or mixtures of these substances.
- the compositions may also contain adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring and perfuming agents.
- Suspensions may contain, in addition to the active ingredient, suspending agents, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methoxide and agar or mixtures of these substances and the like.
- suspending agents for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methoxide and agar or mixtures of these substances and the like.
- compositions for parenteral injection may contain physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions.
- Suitable aqueous and non-aqueous carriers, diluents, solvents or excipients include water, ethanol, polyols and suitable mixtures thereof.
- the compounds of the present invention can be administered alone or in combination with other therapeutic drugs (such as anti-tumor drugs).
- a therapeutically effective dose of the compound of the present invention is applied to a mammal (such as a human) in need of treatment, and the dosage when administered is a pharmaceutically effective dosage.
- a mammal such as a human
- the daily dose is usually 1 to 2000 mg, preferably 20 to 500 mg.
- the specific dosage should also take into account factors such as the route of administration and the patient's health condition, which are all within the skill of a skilled physician.
- the compound of general formula (I) of the present invention can be synthesized through the following synthetic route.
- the synthetic route described below the information involved such as solvents, acids, bases, coupling catalysts and ligands are based on existing organic chemistry knowledge and famous reactions.
- the present invention relates to the synthesis of a class of chiral amine intermediates, and its main synthesis route is as shown in Synthesis Route 1:
- the R 3 -substituted aromatic bromide (I-a) and the tin reagent are cleaved through Stille coupling reaction under acidic conditions to obtain the compound (I-d).
- the Weinreb amide (I-c) can be obtained through the condensation reaction of R3 - substituted aromatic carboxylic acid (I-b) and dimethylhydroxylamine hydrochloride, and then reacted with Grignard reagent to obtain the corresponding ketone (I-d ).
- Ketone (I-d) reacts with (S)-(-)-tert-butylsulfenamide to generate the corresponding ketimine (I-e), which is stereoselectively reduced to obtain (I-f) .
- the sulfinyl group is removed in a hydrogen chloride system to obtain the intermediate chiral amine hydrochloride (I-g).
- the carboxylic acid reacts with a sulfuric acid methanol system or trimethylsilyl diazomethane to obtain the methyl esterification product (II-c).
- reduction reaction such as catalytic hydrogenation, iron powder/dilute hydrochloric acid system, the nitro group is reduced to obtain the amino compound (II-d).
- This compound is halogenated, such as using NCS, to obtain R1 is methoxy and 6-position is chlorinated.
- 2-chloro-5-amino-4-pyridinecarboxylic acid (II-e) can also be used as the starting material, esterified to obtain the methyl ester (II-f), and then halogenated with NBS to obtain a dihalo-substituted pyridine compound. (II-g).
- the above halide and the corresponding boron reagent such as trimethylcyclotriboroxane and cyclopropylboronic acid, are coupled under the catalysis of palladium reagent to obtain compounds (II-h) with different types of R 1 substituents, such as methyl , cyclopropyl compounds.
- the multi-substituted pyridine compound (II-h) and formamidine acetate are cyclized to obtain the pyrimidopyridine ring compound (II-i).
- This compound and the chiral amino compound (II-g) prepared in the synthetic route 1 undergo a condensation reaction to obtain Amino-substituted compound (II-j).
- Chlorine-containing compound (II-j) undergoes a coupling reaction, such as Suzuki, Buchwald, Stille, etc., to introduce compound (I) with R 4 substituent.
- the R 4 group also involves the introduction of some functional groups, which are specifically explained in subsequent examples.
- Diethylamine sulfur trifluoride DAST; 2-(7-azabenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate: HATU; dioxane : dixoane; dichloromethane: DCM; N,N-dimethylformamide: DMF; petroleum ether: PE; ethyl acetate: EA.
- Step 1 Add compound Int-1-a (100g, 0.49mol) and dichloromethane 1L) into a dry 3L round-bottomed flask. The solution was cooled to 0°C, and DAST (120g, 0.17mol) was added dropwise under nitrogen protection. After the addition, the mixture was raised to room temperature and reacted for 16 hours. The reaction solution was poured into ice water, extracted with EA (500mL Bromo-3-(difluoromethyl)-2-fluorobenzene Int-1-b (90g, light yellow oil), yield: 82%.
- EA 500mL Bromo-3-(difluoromethyl)-2-fluorobenzene Int-1-b (90g, light yellow oil), yield: 82%.
- Step 2 Add compound Int-1-b (90g, 0.40mol), tributyl (1-ethoxyvinyl) stannane (173g, 0.48mol) and anhydrous to a dry 2L single-neck round-bottomed flask in sequence.
- Dioxane 900 mL
- triethylamine 101 g, 1.0 mol
- bis(triphenylphosphine) palladium (II) chloride 2.8 g, 4.0 mmol
- Step 3 Add compound Int-1-c (100g, crude product) and anhydrous dioxane (200mL) into a dry 1L single-neck round-bottom flask in sequence.
- the solution was cooled to 0°C, and dilute hydrochloric acid (200 mL, 0.40 mol, 2 M) was added dropwise under nitrogen protection. After the dropwise addition, the mixture was raised to room temperature and reacted for 12 hours.
- the reaction solution was poured into water, and the filtrate was extracted with dichloromethane (300mL 1) Obtain 1-(3-(difluoromethyl)-2-fluorophenyl)ethane-1-one Int-1-d (53g, light yellow oil), yield: 50% in two steps.
- Step 4 Add compound Int-1-d (17g, 90mmol), (S)-2-methylpropane-2-sulfinamide (16g, 0.14mol) and anhydrous to a dry 1L single-neck round-bottomed flask in sequence.
- Step 5 In a dry 1L three-necked flask, add dichloro(p-methylcumyl)ruthenium(II) dimer (1.4g, 2.3mmol), (1S,2R)-1-amino-2, 3-Dihydro-1H-inden-2-ol (0.70g, 4.5mmol), 4A molecular sieve (50g) and isopropanol (100mL) were stirred and reacted at 90°C for 20 minutes under argon protection.
- reaction temperature was cooled to 40°C, a solution of compound Int-1-e (13g, 45mmol) in isopropyl alcohol (450mL) and a solution of potassium tert-butoxide in isopropyl alcohol (113mL, 11mmol, 0.1M) were added in sequence, and reaction was carried out at 40°C 2 Hour.
- the reaction solution was concentrated, saturated brine (100 mL) was added to the residue, and extracted with EA (100 mL x 3). The organic phases were combined and dried over anhydrous sodium sulfate.
- Step 6 Add compound Int-1-f (12.5g, 43mmol) and anhydrous dioxane (100mL) into a dry 1L single-neck round-bottom flask in sequence.
- the solution was cooled to 0°C, and dilute hydrochloric acid dioxane solution (50 mL, 0.20 mol, 4 M) was added dropwise under nitrogen protection. After the dropwise addition, the mixture was raised to room temperature and stirred for 12 hours.
- the reaction solution was concentrated, methyl tert-butyl ether (200 mL) was added to the residue, and stirred for 2 hours.
- the precipitated product was filtered and dried to obtain (R)-1-(3-(difluoromethyl)-2-fluorophenyl).
- Step 1 Add compound Int-2-a (100g, 465mmol), dry DMF (1.5L) and HATU (195g, 512mmol) into a dry 3L three-necked flask. After stirring at room temperature for 30 minutes, add methoxymethyl. Amine hydrochloride (69g, 512mmol) and N,N-diisopropylethylamine (180g, 1.4mol) were stirred at room temperature for 3 hours.
- Step 2 Add compound Int-2-b (20g, 77mmol) and anhydrous tetrahydrofuran to a dry 1L three-necked bottle. (300 mL), cooled to 0°C in an ice bath, methylmagnesium bromide (51 mL, 154 mmol, 3.0 M) was added dropwise, and the reaction was slowly raised to room temperature and stirred for 3 hours.
- methylmagnesium bromide 51 mL, 154 mmol, 3.0 M
- Step 3 Add compound Int-2-c (9.3g, 47mmol), anhydrous tetrahydrofuran (250mL), (R)-(+)-tert-butylsulfenamide (6.4g, 52mmol) and titanium tetraethoxide (50g, 218mmol), stirred and reacted at 80°C for 12 hours under argon protection.
- Step 4 Add dichloro(p-methylcumyl)ruthenium(II) dimer (0.73g, 1.2mmol) and (1S,2R)-1-amino-2,3 in sequence to a 500mL three-necked flask. -Dihydro-1H-inden-2-ol (0.35g, 2.4mmol), 4A molecular sieve (29g) and isopropyl alcohol (60mL), under argon protection, react at 90°C for 20 minutes, the system changes from yellow to deep red .
- Step 5 Add compound Int-2-e (6.1g, 19mmol) and dioxane (50mL) into a dry 250mL single-mouth bottle, cool to 0°C in an ice bath, and add hydrochloric acid/1,4 dioxane dropwise. (25 mL, 100 mmol, 4 M) solution, stirred at room temperature for 12 hours. The reaction solution was concentrated, PE (200 mL) was added to the crude product, stirred for 12 hours, filtered, and dried to obtain (R)-1-(3-bromo-2-methylphenyl)ethane-1-amine hydrochloride Int- 2-f (4.8g, dark gray solid), yield: 100%.
- Step 6 Add compound Int-2-f (6.5g, 30mmol), di-tert-butyl dicarbonate (1.3g, 33mmol), and N,N-diisopropylethylamine (12g) into a dry 250mL single-mouth bottle in sequence. ,31mmol) and anhydrous dichloromethane (150mL), stir at room temperature for 3 hours.
- Step 7 Add compound Int-2-g (7.1g, 23mmol) and zinc cyanide into a dry 250mL single-mouth bottle (3.2g, 27mmol), tetrakis triphenylphosphine palladium (2.6g, 2.3mmol) and anhydrous DMF (100mL), stir and react at 110°C for 3 hours under argon protection. Dilute with water (150 mL), extract with EA (200 mL ⁇ 3), combine the organic phases, wash with saturated brine (100 mL ⁇ 3), dry over anhydrous sodium sulfate, filter, and concentrate the filtrate under reduced pressure. The residue obtained is subjected to silica gel column chromatography.
- Step 8 Add compound Int-2-h (5.0g, 16mmol) and dioxane (50mL) to a dry 250mL single-mouth bottle, cool to 0°C in an ice bath, and add hydrochloric acid/1,4 dioxane dropwise. (25mL, 100mmol, 4M) solution, warmed to room temperature and stirred for 15 hours. The reaction solution was concentrated, methyl tert-butyl ether (200 mL) was added, stirred for 12 hours, filtered, and dried to obtain (R)-3-(1-aminoethyl)-2-toluonitrile hydrochloride Int-2 (3.0 g , white solid), yield: 80%.
- Step 2 Dissolve compound A-1-b (9.0g, 48.1mmol) and N-bromosuccinimide (10.3g, 57.8mmol) in 150mL DMF, and stir at 85°C for 16 hours under nitrogen protection. .
- the reaction solution was extracted with EA, the organic phase was collected and dried over anhydrous sodium sulfate, then cold water was added to the organic phase at 0°C, filtered and the precipitated product was collected to obtain compound A-1-c (13g, brown solid). Yield: 100%.
- LCMS(ESI): m/z 265[M+H] + .
- Step 5 Dissolve compound A-1-e (250mg, 1.3mmol) and compound Int-1 (226mg, 1.4mmol) in an eggplant-shaped flask filled with 10mL DMF, then add PyBOP (733mg, 1.4mmol), N,N-diisopropylethylamine (3.3g, 25.6mmol) was stirred at 50°C for 10 hours under nitrogen protection.
- the reaction solution was extracted with EA, the organic phase was collected and dried over anhydrous sodium sulfate, the organic phase was filtered and concentrated under reduced pressure. The residue was purified by normal phase column chromatography to obtain compound A-1-f (180 mg, yellow solid), yield: 39%.
- LCMS (ESI): m/z 367.1[M+H] + .
- Step 6 Dissolve compound A-1-f (180 mg, 0.14 mmol) and N-Boc-piperazine (275 mg, 1.5 mmol) in a 3 mL dioxane sealed tube, and add cesium carbonate ( 482 mg, 1.5 mmol), Binap (60 mg, 0.1 mmol) and NHC-Pd (34 mg, 0.05 mmol), stirred at 110°C for 8 hours under nitrogen protection.
- the reaction solution was extracted with EA, the organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was preparatively purified to obtain compound A-1-g (80 mg, yellow solid), yield: 32%.
- LCMS (ESI): m/z 517.2[M+H] + .
- Step 7 Dissolve compound A-1-g (80 mg, 0.16 mmol) in 3 mL of methylene chloride, add trifluoroacetic acid (1 mL) to the reaction system, and stir at room temperature for 1 hour. The reaction solution was concentrated under reduced pressure to obtain compound A-1-h (60 mg, yellow oil), yield: 94%.
- LCMS (ESI): m/z 417.2[M+H] + .
- Step 2 Add HCl (5 mL, 2.0 N, aq.) to a solution of compound A-10-b (200 mg, 0.50 mmol) in dioxane (10 mL), and react at room temperature for 4 hours. Adjust the pH to 6 with sodium hydroxide solution (2.0N), extract with EA, filter and concentrate under reduced pressure. The residue (crude product A-10-c) is directly used in the next reaction.
- LCMS(ESI): m/z 375.1[M+H] + .
- Step 3 Slowly add methylmagnesium bromide (0.32 mL, 0.32 mmol) into a solution of compound A-10-c (60 mg, 0.16 mmol) in THF (3 mL), and react at room temperature overnight. Quenched with saturated ammonium chloride solution, then extracted with ethyl acetate, filtered and concentrated under reduced pressure, the residue was purified by reverse phase preparative purification to obtain A-10 (11.0 mg, yield: 17%).
- Step 2 Add compound A-11-a (40 mg, 0.09 mmol), palladium on carbon (0.02 mmol) and 10 mL methanol to a single-mouth bottle, stir at room temperature overnight under a hydrogen atmosphere, and perform reverse preparative purification to obtain the target compound A-11 (20 mg ), white solid, yield: 50%.
- LCMS (ESI): m/z 458.2[M+H] + .
- Step 1 Dissolve compound A-12 (80 mg, 0.17 mmol) in 10 mL dichloromethane, cool the dry ice-EA system to low temperature, and add DAST (1.2 eq). After the addition is completed, the mixture is naturally raised to room temperature and stirred overnight. The reaction was quenched with ammonium chloride, dichloromethane-water system was added, and the layers were separated. The organic phase was collected, dried over anhydrous magnesium sulfate, and concentrated to obtain crude compound A-13-a, which was directly used in the next step.
- Step 2 Add the crude compound A-13-a to the sealed tube, dissolve it in 5 mL of methanol, and then slowly add 20 mg of sodium methoxide. Sealed, react at 70°C for 2 hours. Add a small amount of water to quench. The reaction system was prepared by reverse phase to obtain the target compound A-13 (13.2 mg) as a white solid. The two-step yield: 16%.
- LCMS (ESI): m/z 488.1[M+H] + .
- Step 1 Add compound A-13-a (50 mg, 0.11 mmol), 1 mL ammonia water, and dioxane 2 into the sealed tube. mL. Seal and react at 100°C for 2 hours. The reaction solution was prepared by reverse phase to obtain target compound A-14 (8.3 mg) as a white solid, yield: 16%.
- LCMS (ESI): m/z 473.1[M+H] + .
- Step 1 Dissolve compound A-1-f (50mg, 0.14mmol) and compound A-22-a (71.7mg, 0.68mmol) into 1,4-dioxane (2mL) in a sealed tube, and then Add NHC-Pd (7.5mg), BINAP (8.5mg, 0.014mmol) and Cs 2 CO 3 (134.0 mg, 0.41 mmol), reacted at 110°C for 8 hours under nitrogen protection.
- reaction solution was extracted with saturated ammonium chloride solution and EA, the organic phase was backwashed with saturated brine, dried over sodium sulfate, filtered and concentrated under reduced pressure, and the residue was purified by neutral reversed phase preparation to obtain compound A-22 (28.0 mg, Light yellow solid), yield: 45.5%.
- LCMS (ESI): m/z 452.0[M+H] + .
- Step 1 Add compound A-1-f (50 mg, 0.14 mmol), 1,4-dioxane (5 mL), A-35-a (58 mg, 0.68 mmol), and cesium carbonate in sequence to a dry sealed tube. (137 mg, 0.41 mmol), NHC-Pd (9.3 mg, 0.01 mmol), BINAP (8.5 mg, 0.01 mmol); stir overnight at 110°C under nitrogen protection. Cool, quench the reaction solution with ammonium chloride solution, add EA for extraction, backwash the organic phase with saturated brine, dry over sodium sulfate, and concentrate under reduced pressure. The residue is purified by flash column chromatography to obtain white solid A-35 (21.6 mg, yield: 41%).
- Test Example 1 Detection of the Inhibitory Effect of Compounds on KRAS-G12C/SOS1
- IC 50 represents the inhibitory ability of the compound on KRAS-G12C/SOS1. The lower the IC 50 value, the stronger its inhibitory ability.
- BI-3406 was used as a positive control compound.
- KRASG12C/SOS Binding kit (Cisbio, cat. 63ADK000CB16PEG); DMSO (Sigma, cat. D8418-1L); 384-well white plate (PerkinElmer, cat. 6007290)
- the concentration of the test compound is 5000nM, dilute it into a 100% DMSO solution of 200 times the final concentration in a 384-well plate, and dilute the compound 3 times to 10 concentrations.
- Inhibition% (Max signal-Compound signal)/(Max signal-Min signal) ⁇ 100; where Min signal is the mean value of the negative control wells and Max signal is the mean value of the positive control wells.
- a in IC 50 means IC 50 ⁇ 200nM
- B means 200nM ⁇ IC 50 ⁇ 2000nM
- C means 2000nM ⁇ IC 50 ⁇ 5000nM
- D means IC 50 > 5000nM.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne une classe de composés ayant une structure cyclique pyrimido à six chaînons, des compositions pharmaceutiques les comprenant, et leur utilisation. Les composés ont une structure représentée par la formule (I) ci-dessous. Des expériences prouvent que les composés selon la présente invention ont une excellente activité inhibitrice contre l'interaction KRAS-G12C/SOS1. Par conséquent, les composés de formule I ont le potentiel d'être un inhibiteur de SOS1 et peuvent être développés en un médicament pour le traitement de maladies associées à celui-ci.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210714643.7A CN117304182A (zh) | 2022-06-22 | 2022-06-22 | 一类具有嘧啶并六元环结构的化合物、包含其的药物组合物及其应用 |
CN202210714643.7 | 2022-06-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023246837A1 true WO2023246837A1 (fr) | 2023-12-28 |
Family
ID=89287209
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2023/101588 WO2023246837A1 (fr) | 2022-06-22 | 2023-06-21 | Classe de composés ayant une structure cyclique pyrimido à six chaînons, compositions pharmaceutiques les comprenant et leur utilisation |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN117304182A (fr) |
WO (1) | WO2023246837A1 (fr) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105793254A (zh) * | 2012-11-29 | 2016-07-20 | 默克专利有限公司 | 氮杂喹唑啉羧酰胺衍生物 |
WO2021074227A1 (fr) * | 2019-10-15 | 2021-04-22 | Bayer Aktiengesellschaft | 2-méthyl-aza-quinazolines |
WO2021083936A1 (fr) * | 2019-11-01 | 2021-05-06 | Syngenta Crop Protection Ag | Composés hétéroaromatiques bicycliques fusionnés à action pesticide |
WO2021228028A1 (fr) * | 2020-05-09 | 2021-11-18 | 正大天晴药业集团股份有限公司 | Inhibiteur de sos1 contenant du phosphore |
CN114685488A (zh) * | 2020-12-31 | 2022-07-01 | 南京圣和药业股份有限公司 | 作为sos1抑制剂的化合物及其应用 |
CN115785088A (zh) * | 2021-09-09 | 2023-03-14 | 南京圣和药业股份有限公司 | 作为sos1抑制剂的化合物及其应用 |
WO2023067546A1 (fr) * | 2021-10-21 | 2023-04-27 | Satyarx Pharma Innovations Pvt Ltd | Nouveaux dérivés bicycliques hétéroaryles utilisés en tant qu'inhibiteurs de l'interaction protéine-protéine sos1 : kras |
-
2022
- 2022-06-22 CN CN202210714643.7A patent/CN117304182A/zh active Pending
-
2023
- 2023-06-21 WO PCT/CN2023/101588 patent/WO2023246837A1/fr unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105793254A (zh) * | 2012-11-29 | 2016-07-20 | 默克专利有限公司 | 氮杂喹唑啉羧酰胺衍生物 |
WO2021074227A1 (fr) * | 2019-10-15 | 2021-04-22 | Bayer Aktiengesellschaft | 2-méthyl-aza-quinazolines |
WO2021083936A1 (fr) * | 2019-11-01 | 2021-05-06 | Syngenta Crop Protection Ag | Composés hétéroaromatiques bicycliques fusionnés à action pesticide |
WO2021228028A1 (fr) * | 2020-05-09 | 2021-11-18 | 正大天晴药业集团股份有限公司 | Inhibiteur de sos1 contenant du phosphore |
CN114685488A (zh) * | 2020-12-31 | 2022-07-01 | 南京圣和药业股份有限公司 | 作为sos1抑制剂的化合物及其应用 |
CN115785088A (zh) * | 2021-09-09 | 2023-03-14 | 南京圣和药业股份有限公司 | 作为sos1抑制剂的化合物及其应用 |
WO2023067546A1 (fr) * | 2021-10-21 | 2023-04-27 | Satyarx Pharma Innovations Pvt Ltd | Nouveaux dérivés bicycliques hétéroaryles utilisés en tant qu'inhibiteurs de l'interaction protéine-protéine sos1 : kras |
Also Published As
Publication number | Publication date |
---|---|
CN117304182A (zh) | 2023-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113286794B (zh) | Kras突变蛋白抑制剂 | |
WO2020259432A1 (fr) | Inhibiteur de kras-g12c | |
WO2021218110A1 (fr) | Composé de benzothiazolyle biaryle, son procédé de préparation et son utilisation | |
WO2019158019A1 (fr) | Composé cyclique fusionné à une pyrimidine, son procédé de préparation et son application | |
WO2023051716A1 (fr) | Inhibiteur de parp dérivé d'hétéroaryle et son utilisation | |
TW202144345A (zh) | Kras突變蛋白抑制劑 | |
TW201827426A (zh) | 具有glp-1受體促效作用的吡唑并吡啶衍生物 | |
JP2019515931A (ja) | イソキノリン−3イル−カルボキサミドならびにその調製および使用の方法 | |
CN110156786A (zh) | 嘧啶并环化合物及其制备方法和应用 | |
WO2021143701A1 (fr) | Composé hétérocyclique de pyrimidine-4(3h)-cétone, son procédé de préparation et son utilisation en médecine et en pharmacologie | |
CN107567450B (zh) | 用作tnf抑制剂的杂环化合物 | |
CN114728962A (zh) | 血浆激肽释放酶抑制剂及其用途 | |
CN113527293B (zh) | Kras g12c突变蛋白抑制剂及其药物组合物、制备方法和用途 | |
JP2014511355A (ja) | ヒストンデアセチラーゼ阻害薬並びにその組成物及び使用方法 | |
WO2017101796A1 (fr) | Dérivé de phtalazinone, et procédé de préparation et utilisation associés | |
CN116323625A (zh) | 杂环类衍生物、其制备方法及其医药上的用途 | |
WO2020143763A1 (fr) | Composés d'halogénoallylamine et leur utilisation | |
WO2019228404A1 (fr) | Nouveau inhibiteur de phosphoïnositide 3-kinase et procédé de préparation et d'utilisation associé | |
WO2020108661A1 (fr) | Composé hétérocyclique utilisé en tant qu'inhibiteur de cdk-hdac à double canal | |
WO2023098832A1 (fr) | Dérivés de pyridopyrimidine servant d'inhibiteurs à petites molécules de mutation kras d'enzyme gtp | |
WO2023280237A1 (fr) | Synthèse et utilisation d'agent de dégradation de phosphatase | |
WO2023202623A1 (fr) | Composé inhibiteur de polq et son utilisation | |
WO2023232069A1 (fr) | Dérivé d'azaquinolinone, son procédé de préparation et son utilisation | |
WO2023227052A1 (fr) | Inhibiteur de parp dérivé bicyclique et son utilisation | |
WO2022170947A1 (fr) | Dérivés de tétrahydronaphtyridine utilisés en tant qu'inhibiteurs de g12c mutants kras, leur procédé de préparation et leur utilisation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23826482 Country of ref document: EP Kind code of ref document: A1 |